ABN AMRO Bank N.V. Cuts Stock Holdings in AbbVie Inc. $ABBV

Key Points

• ABN AMRO Bank N.V. trimmed its AbbVie stake by 2.1% in the fourth quarter, selling 19,212 shares and ending with 913,863 shares worth about $208.4 million. AbbVie still made up roughly 2.0% of the bank’s portfolio.
• AbbVie reported stronger-than-expected quarterly results, posting EPS of $2.65 versus estimates of $2.59 and revenue of $15 billion versus $14.72 billion expected. Revenue rose 12.4% year over year, underscoring continued momentum.
• The company reaffirmed shareholder returns and Wall Street remains constructive, with a quarterly dividend of $1.73 per share and an annualized yield of 3.4%. Analysts currently rate the stock a Moderate Buy, with a consensus price target of $252.90.

ABN AMRO Bank N.V. reduced its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 913,863 shares of the company's stock after selling 19,212 shares during the period. AbbVie accounts for about 2.0% of ABN AMRO Bank N.V.'s portfolio, making the stock its 19th largest holding. ABN AMRO Bank N.V. owned 0.05% of AbbVie worth $208,446,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ABBV. Wellington Management Group LLP increased its stake in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after buying an additional 8,646,424 shares in the last quarter. Vanguard Group Inc. increased its stake in AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock worth $41,306,353,000 after buying an additional 3,032,438 shares in the last quarter. Raymond James Financial Inc. grew its position in shares of AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of AbbVie by 31.8% in the third quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company's stock valued at $1,685,918,000 after purchasing an additional 1,758,657 shares in the last quarter. Finally, Amundi grew its position in shares of AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company's stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Performance

Shares of AbbVie stock opened at $201.24 on Monday. The firm has a market capitalization of $355.83 billion, a price-to-earnings ratio of 99.13, a PEG ratio of 0.70 and a beta of 0.32. AbbVie Inc. has a fifty-two week low of $176.57 and a fifty-two week high of $244.81. The stock has a 50 day moving average of $213.18 and a 200 day moving average of $221.00.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The firm's revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.46 earnings per share. Analysts forecast that AbbVie Inc. will post 14.32 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. AbbVie's payout ratio is presently 340.89%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ABBV. Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. The Goldman Sachs Group restated a "neutral" rating and issued a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Sanford C. Bernstein restated a "market perform" rating on shares of AbbVie in a research report on Thursday, February 5th. Barclays began coverage on AbbVie in a research report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 price target for the company. Finally, Morgan Stanley upped their price target on AbbVie from $270.00 to $278.00 and gave the company an "overweight" rating in a research report on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $252.90.

Insider Buying and Selling at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie continued to draw bullish attention after reporting strong first-quarter results, with revenue and earnings coming in ahead of expectations and showing that growth is extending beyond Humira into newer drugs like Skyrizi and Rinvoq. AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.
• Positive Sentiment: AbbVie completed an early safety study for ABBV-142, which may improve investor confidence in the company’s pipeline and future oncology growth prospects. AbbVie Completes Early Safety Study for ABBV-142, Nudging Pipeline Hopes Higher
• Positive Sentiment: AbbVie and adMare BioInnovations named RIME Therapeutics as a Biotech Innovators Award winner, reinforcing AbbVie’s efforts to support early-stage biotech innovation and build optionality around its pipeline ecosystem. AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner
• Positive Sentiment: Skyrizi ranked ahead of J&J’s Tremfya in April drug ad spending, signaling continued competitive momentum and heavy marketing support for one of AbbVie’s key growth brands. AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
• Neutral Sentiment: Analyst commentary and Q1 earnings-call recaps highlighted ongoing interest in AbbVie’s post-Humira growth strategy, but these pieces were mostly interpretive rather than new market-moving disclosures. 5 must-read analyst questions from AbbVie’s Q1 earnings call
• Neutral Sentiment: Coverage on SKYRIZI expansion and reimbursement progress in Canada suggests continued international adoption, but the article framed these as part of an already constructive longer-term thesis rather than a single new catalyst. Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?
• Negative Sentiment: One relative headwind is that ABBV shares have recently traded below key moving averages, reflecting some investor caution even as fundamentals remain solid.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.